Nekhlyudov Larissa, Li Rong, Fletcher Suzanne W
Department of Ambulatory Care and Prevention, Harvard Medical School/Harvard Pilgrim Health Care, Boston, MA 02215, USA.
Health Expect. 2008 Dec;11(4):366-75. doi: 10.1111/j.1369-7625.2008.00514.x.
Informed decision making regarding screening mammography is recommended for women under age 50. To what extent it occurs in clinical settings is unclear.
Using a mailed instrument, we surveyed women aged 40-44 prior to their first screening mammogram. All women were members of a large health maintenance organization and received care at a large medical practice in the Greater Boston area. The survey measured informed decision making, decisional conflict, satisfaction, and screening mammography knowledge and intentions to undergo screening.
Ninety-six women responded to the survey (response rate 47%). Overall, women reported limited informed decision making regarding screening mammography, both with respect to information exchange and involvement in the decision process. Less than half (47%) reported discussing the benefits of screening; 23% the uncertainties; and only 7% the harms. About 30% reported discussing the nature of the decision or clinical issue; and 29% reported their provider elicited their preferred role in the decision; 38% their preferences; and 24% their understanding of the information. Women who were uninformed had higher decisional conflict (2.37 vs. 1.83, P=0.005) about screening mammography and were more likely to be dissatisfied with the information and involvement. Women's screening mammography knowledge was limited in most areas; however being presented with information did not diminish their intentions to undergo screening.
Informed decision making before initiating screening mammography is limited in this setting. There appears to be little indication that information about the benefits and harms decreases women's intentions to undergo screening. Methods to communicate information to women before initiating screening mammography are needed.
建议50岁以下女性在进行乳腺钼靶筛查时做出明智的决策。目前尚不清楚这种情况在临床环境中发生的程度。
我们使用邮寄调查问卷的方式,对40 - 44岁首次进行乳腺钼靶筛查前的女性进行了调查。所有女性均为一家大型健康维护组织的成员,并在大波士顿地区的一家大型医疗机构接受治疗。该调查衡量了明智决策、决策冲突、满意度、乳腺钼靶筛查知识以及接受筛查的意愿。
96名女性回复了调查(回复率47%)。总体而言,女性表示在乳腺钼靶筛查的明智决策方面,无论是信息交流还是参与决策过程都很有限。不到一半(47%)的女性报告讨论了筛查的益处;23%讨论了不确定性;只有7%讨论了危害。约30%的女性报告讨论了决策或临床问题的性质;29%报告其医疗服务提供者询问了她们在决策中希望扮演的角色;38%询问了她们的偏好;24%询问了她们对信息的理解。未充分了解信息的女性在乳腺钼靶筛查方面的决策冲突更高(2.37对1.83,P = 0.005),并且更有可能对信息和参与情况不满意。女性在大多数领域的乳腺钼靶筛查知识有限;然而,提供信息并没有降低她们接受筛查的意愿。
在这种情况下,开始乳腺钼靶筛查前的明智决策是有限的。几乎没有迹象表明关于益处和危害的信息会降低女性接受筛查的意愿。需要采取方法在开始乳腺钼靶筛查前向女性传达信息。